bruton tyrosine kinase — TargetMol Chemicals

Cat No.	Product Name	Synonyms	Targets
T16730	Remibrutinib		BTK
	Remibrutinib inhibits BTK activity with an IC50 value of 0.023 μM in blood. Remibrutinib is an effective and orally active Bruton tyrosine kinase inhibitor (IC50: 1 nM). Remibrutinib has the potential for Chronic urticar...		BTK
T9125	Tolebrutinib	PRN2246,SAR442168	BTK
	Tolebrutinib (PRN2246) is a potent, selective, orally active and brain-penetrant Bruton tyrosine kinase (BTK) inhibitor(IC50s of 0.4 and 0.7 nM in Ramos B cells and in HMC microglia cells, respectively). It exhibits effi...		BTK
T14692	BMX-IN-1	BMX kinase inhibitor	BTK
	BMX-IN-1 (BMX kinase inhibitor) is a selective inhibitor of bone marrow tyrosine kinase on chromosome X (BMX, IC50 = 8 nM) and the related Bruton’s tyrosine kinase (BTK, IC50 = 10.4 nM), but BMX-IN-1 is more than 47-656 ...		BTK
T1976	RN486		BTK
	RN486 is an effective and specific BTK inhibitor (IC50: 4 nM).		BTK
T5138	BMS-986142		BTK
	BMS-986142 is a potent and highly selective reversible BTK inhibitor (IC50: 0.5 nM).		BTK
T10626	(Rac)-IBT6A		Others , BTK
	(Rac)-IBT6A is a racemate of IBT6A. IBT6A is an impurity of Ibrutinib and can be used in the synthesis of IBT6A Ibrutinib dimer and IBT6A adduct.		Others , BTK
T16157	MT-802		BTK , PROTACs
	MT-802 is an effective BTK degrader based on PROTAC technology (DC50: 1 nM). MT-802 has the potential to treat C481S mutant chronic lymphocytic leukemia (CLL).		BTK , PROTACs
T10625	IBT6A		BTK
	IBT6A is an impurity of Ibrutinib. Ibrutinib is a Btk inhibitor (IC50: 0.5 nM). IBT6A can be used in the synthesis of IBT6A Ibrutinib dimer and IBT6A adduct.		BTK
T36287	Pirtobrutinib		BTK
	Pirtobrutinib (LOXO-305) is an advanced BTK inhibitor that displays high selectivity and operates through a non-covalent mechanism. This compound effectively inhibits various BTK C481 substitution mutations, leading to t...		BTK
T6217	LFM-A13		PLK , JAK , BTK
	LFM-A13（IC50=2.5 μM）, a specific Bruton's tyrosine kinase (BTK), is more than 100-fold specificity than other protein kinases, such as JAK1, JAK2, HCK, EGFR, and IRK.		PLK , JAK , BTK
T2472	CGI-1746		BTK , Autophagy
	CGI1746 is a potent and highly selective small-molecule Btk inhibitor with IC50 of 1.9 nM.		BTK , Autophagy
TQ0242	Fenebrutinib	GDC-0853	BTK
	Fenebrutinib (GDC-0853) is a selective and noncovalent Btk inhibitor (Ki: 0.91 nM).		BTK
T5407	Branebrutinib	BMS986195	BTK
	Branebrutinib (BMS986195) is a potent, covalent inhibitor of Bruton's tyrosine kinase (BTK), >5,000-fold selective over all kinases outside of the Tec family (IC50 <1 nM for BTK).		BTK
T12542	Rilzabrutinib	PRN1008	EGFR , Others , HER , BTK
	Rilzabrutinib (PRN1008) is a reversible covalent, selective and oral active inhibitor of Bruton’s Tyrosine Kinase (BTK)(IC50 of 1.3 nM).		EGFR , Others , HER , BTK
T9706	BTK inhibitor 17		BTK
	BTK inhibitor 17 is a potent irreversible BTK inhibitor (IC50 = 2.1 nM). BTK inhibitor 17 can be used in rheumatoid arthritis studies.		BTK
T14323	ARQ 531		BTK
	ARQ-531 is a potent and orally active BTK inhibitor with potential antineoplastic activity, with IC50s of 0.85 nM and 0.39 nM for WT-BTK and C481S-BTK, respectively.		BTK
T2302	CNX-774	CNX 774	BTK
	CNX-774 is a highly specific, irreversible, and orally active BTK inhibitor (IC50<1 nM).		BTK
T12317	Orelabrutinib	ICP-022	BTK
	Orelabrutinib (ICP-022) is an orally active and irreversible inhibitor of Bruton's tyrosine kinase (BTK).		BTK
T7584	Zanubrutinib	BGB-3111	BTK
	Zanubrutinib (BGB-3111) is an inhibitor of Bruton tyrosine kinase (BTK).		BTK
T9192	BIIB068		BTK
	BIIB068 is an selective, reversible and orally active BTK inhibitor (IC50 = 1 nM, Kd = 0.3 nM). BIIB068 is 400 times more selective for BTK than other kinases.		BTK